Stop TB Partnership and Johnson & Johnson announce price reduction for bedaquiline
Stop TB Partnership and Johnson & Johnson, with support from USAID and the Global Fund, announce price reduction for bedaquiline for treatment of drug-resistant TB in low- and middle-income countries.
6 July 2020, Geneva, Switzerland – The Stop TB Partnership and Johnson & Johnson – with support from the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund), and the U.S. Agency for International Development (USAID) – today announced joint efforts to help enable low- and middle-income countries to rapidly scale up use of SIRTURO® (bedaquiline) 100 mg tablets in support of new, recently-released World Health Organization (WHO) treatment guidelines.
To read the full press release, click here.
Source: Stop TB Partnership